2016
Serum mass profile signature as a biomarker of early lung cancer
Widlak P, Pietrowska M, Polanska J, Marczyk M, Ros-Mazurczyk M, Dziadziuszko R, Jassem J, Rzyman W. Serum mass profile signature as a biomarker of early lung cancer. Lung Cancer 2016, 99: 46-52. PMID: 27565913, DOI: 10.1016/j.lungcan.2016.06.011.Peer-Reviewed Original ResearchConceptsEarly lung cancerLung cancerNegative predictive valuePredictive valueComputed tomographyEarly-stage lung cancerLow-dose computed tomographyIndeterminate pulmonary nodulesStage lung cancerPotential clinical usefulnessPositive predictive valueValidation cohortHealthy controlsClinical usefulnessDiscovery cohortBlood samplesIndependent cohortWeight serum fractionsPulmonary nodulesIndependent sample setCancerPatientsHealthy participantsMolecular biomarkersCohort
1982
Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications.
Bunn P, Krasnow S, Makuch R, Schlam M, Schechter G. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. Blood 1982, 59: 528-35. PMID: 6800416, DOI: 10.1182/blood.v59.3.528.bloodjournal593528.Peer-Reviewed Original ResearchConceptsTumor DNA contentMyeloma patientsPlasma cell myelomaAneuploid tumor cellsPlasma cellsWaldenstrom's macroglobulinemiaCell myelomaTumor cellsTime of diagnosisTime of relapseIndependent prognostic significanceCourse of illnessClinical drug resistancePotential clinical usefulnessBone marrow cellsDNA contentClinical relapseRenal failureSerum creatininePrognostic significanceDiploid tumorsAneuploid tumorsDevelopment of aneuploidyClinical significanceClinical usefulnessFlow Cytometric Analysis of DNA Content of Bone Marrow Cells in Patients With Plasma Cell Myeloma: Clinical Implications
Bunn P, Krasnow S, Makuch R, Schlam M, Schechter G. Flow Cytometric Analysis of DNA Content of Bone Marrow Cells in Patients With Plasma Cell Myeloma: Clinical Implications. Blood 1982, 59: 528-535. DOI: 10.1182/blood.v59.3.528.528.Peer-Reviewed Original ResearchTumor DNA contentMyeloma patientsPlasma cell myelomaAneuploid tumor cellsPlasma cellsWaldenstrom's macroglobulinemiaCell myelomaTumor cellsIndependent prognostic significanceTime of diagnosisTime of relapseCourse of illnessClinical drug resistancePotential clinical usefulnessBone marrow cellsFlow cytometric analysisDNA contentClinical relapseRenal failureSerum creatininePrognostic significanceDiploid tumorsAneuploid tumorsDevelopment of aneuploidyClinical significance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply